These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 36572925)

  • 21. Prevalence and Specific Manifestations of Non-alcoholic Fatty Liver Disease (NAFLD) and Diabetes Mellitus Type 2 Association in a Moroccan Population: A Cross-sectional Study.
    Assarrar I; Messaoudi N; Ongoth FEM; Abdellaoui W; Malki A; Rouf S; Abda N; Ismaili Z; Latrech H
    Rev Diabet Stud; 2022 Sep; 18(3):140-145. PubMed ID: 36309775
    [No Abstract]   [Full Text] [Related]  

  • 22. Histopathological differences in patients with biopsy-proven non-alcoholic fatty liver disease with and without type 2 diabetes.
    Aller de la Fuente R; Mora Cuadrado N; Tafur C; López Gómez JJ; Gómez de la Cuesta S; García Sánchez MC; Antolin Melero B; de Luis Román DA
    Endocrinol Diabetes Nutr (Engl Ed); 2018; 65(6):354-360. PubMed ID: 29477355
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of nonalcoholic fatty liver disease and liver cirrhosis in Chinese adults with type 2 diabetes mellitus.
    Han X; Zhang X; Liu Z; Fan H; Guo C; Wang H; Gu Y; Zhang T
    J Diabetes; 2024 May; 16(5):e13564. PubMed ID: 38664879
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibrosis Progression Rate in Biopsy-Proven Nonalcoholic Fatty Liver Disease Among People With Diabetes Versus People Without Diabetes: A Multicenter Study.
    Huang DQ; Wilson LA; Behling C; Kleiner DE; Kowdley KV; Dasarathy S; Amangurbanova M; Terrault NA; Diehl AM; Chalasani N; Neuschwander-Tetri BA; Sanyal AJ; Tonascia J; ; Loomba R
    Gastroenterology; 2023 Aug; 165(2):463-472.e5. PubMed ID: 37127100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severity of non-alcoholic steatohepatitis is not linked to testosterone concentration in patients with type 2 diabetes.
    Dayton KA; Bril F; Barb D; Lai J; Kalavalapalli S; Cusi K
    PLoS One; 2021; 16(6):e0251449. PubMed ID: 34077443
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pathologic relevance of metabolic criteria in patients with biopsy-proven nonalcoholic fatty liver disease and metabolic dysfunction associated fatty liver disease: A multicenter cross-sectional study in China.
    Yang RX; Zou ZS; Zhong BH; Deng H; He FP; Shi JP; Zhao CY; Mi YQ; Zhou YJ; Di FS; Zheng RD; Du Q; Shang J; Popovic B; Chen J; Fan JG
    Hepatobiliary Pancreat Dis Int; 2021 Oct; 20(5):426-432. PubMed ID: 34246549
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Urine uric acid excretion is associated with nonalcoholic fatty liver disease in patients with type 2 diabetes.
    Zhao CC; Wang AP; Li LX; Li TT; Chen MY; Zhu Y; Yu TP; Bao YQ; Jia WP
    J Diabetes Complications; 2016 Aug; 30(6):1074-80. PubMed ID: 27161518
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Nonalcoholic Fatty Liver Disease: The New Complication of Type 2 Diabetes Mellitus.
    Bril F; Cusi K
    Endocrinol Metab Clin North Am; 2016 Dec; 45(4):765-781. PubMed ID: 27823604
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Calleja JL; García-Monzón C; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Albillos A; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Guerra MH; Augustín S; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero Gómez M;
    J Hepatol; 2020 Jul; 73(1):17-25. PubMed ID: 32147361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum Retinol-Binding Protein Levels Are Associated with Nonalcoholic Fatty Liver Disease in Chinese Patients with Type 2 Diabetes Mellitus: A Real-World Study.
    Zhang ZH; Ke JF; Lu JX; Liu Y; Wang AP; Li LX
    Diabetes Metab J; 2022 Jan; 46(1):129-139. PubMed ID: 34372627
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.
    Kabbany MN; Conjeevaram Selvakumar PK; Watt K; Lopez R; Akras Z; Zein N; Carey W; Alkhouri N
    Am J Gastroenterol; 2017 Apr; 112(4):581-587. PubMed ID: 28195177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Noninvasive identification of probable fibrotic nonalcoholic steatohepatitis across the spectrum of glucose tolerance in the United States.
    Ciardullo S; Carbone M; Invernizzi P; Perseghin G
    Diabetes Res Clin Pract; 2023 May; 199():110679. PubMed ID: 37094749
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increased Body Mass Index and Type 2 Diabetes Are the Main Predictors of Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in Liver Biopsies of Patients With Human Immunodeficiency Virus Monoinfection.
    Maurice JB; Goldin R; Hall A; Price JC; Sebastiani G; Morse CG; Prat LI; Perazzo H; Garvey L; Ingiliz P; Guaraldi G; Tsochatzis E; Lemoine M
    Clin Infect Dis; 2021 Oct; 73(7):e2184-e2193. PubMed ID: 32877569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes.
    Sako S; Takeshita Y; Takayama H; Goto H; Nakano Y; Ando H; Tsujiguchi H; Yamashita T; Arai K; Kaneko S; Nakamura H; Harada K; Honda M; Takamura T
    Diabetes; 2023 Sep; 72(9):1297-1306. PubMed ID: 37343270
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis.
    En Li Cho E; Ang CZ; Quek J; Fu CE; Lim LKE; Heng ZEQ; Tan DJH; Lim WH; Yong JN; Zeng R; Chee D; Nah B; Lesmana CRA; Bwa AH; Win KM; Faulkner C; Aboona MB; Lim MC; Syn N; Kulkarni AV; Suzuki H; Takahashi H; Tamaki N; Wijarnpreecha K; Huang DQ; Muthiah M; Ng CH; Loomba R
    Gut; 2023 Nov; 72(11):2138-2148. PubMed ID: 37491159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Screening for nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography - a prospective, cross sectional study.
    Mikolasevic I; Domislovic V; Turk Wensveen T; Delija B; Klapan M; Juric T; Lukic A; Mijic A; Skenderevic N; Puz P; Ostojic A; Krznaric Z; Radic-Kristo D; Filipec Kanizaj T; Stimac D
    Eur J Intern Med; 2020 Dec; 82():68-75. PubMed ID: 32839076
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: A systematic review and meta-analysis.
    Younossi ZM; Golabi P; de Avila L; Paik JM; Srishord M; Fukui N; Qiu Y; Burns L; Afendy A; Nader F
    J Hepatol; 2019 Oct; 71(4):793-801. PubMed ID: 31279902
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FSTL3 partially mediates the association of increased nonalcoholic fatty liver disease fibrosis risk with acute myocardial infarction in patients with type 2 diabetes mellitus.
    Duan W; Shi R; Yang F; Zhou Z; Wang L; Huang Z; Zang S
    Cardiovasc Diabetol; 2023 Oct; 22(1):297. PubMed ID: 37904173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.